Coeptis Therapeutics, Inc.

NASDAQ:COEP

Biotechnology

Healthcare
$14.64 +4.68%

+$0.73 today

Market cap
$57.63M
Beta
-0.43
P/E (TTM)
-8.3
EPS (TTM)
-$1.97
52W Low $6.80High $21.41

Volume 0.18M

Average 0.05M

COEP Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Coeptis Therapeutics, Inc.NASDAQ: COEP

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $4.02M (cash outflow) rose 17.5% year over year, ahead of the +12.6% change in trailing-twelve-month net income. Sequentially, it rose 147.8% from the prior quarter. Over 3 fiscal years it compounded at -31.8% a year.

Context

  • Net income amounted to 874.3% of revenue in FY2025.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of -$14.4M (+20.8%) for the fiscal year ending Dec 2026, a step up from the +9.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.02M+147.8% QoQ
Last fiscal yearDec 2025
-$11.92M+9.6% YoY
LTMMar 2026
-$12.72M+12.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.5%+122.7%+105.1 pp
1 year+9.6%+20.8%+11.3 pp
3-year CAGR-31.8%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(11.92M) USD
Year-over-year change
-9.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How COEP compares with its peers on the latest reported figures

  • COEP's LTM Mar 2026 net income of $12.72M is the 8th largest of the 9 companies compared; the peer median is $42.75M.
  • Its year-over-year change of +12.6% is the 5th highest of 9, against a peer median of +19.0%.
  • Net income amounts to 899.5% of revenue for COEP, versus a peer median of 599.6%.
COEP Competitors Peer median
Net Income for COEP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OSTXOS Therapies IncorporatedLTM Mar 2026$28.76B +254398.4%+1562.8%—
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$194.97M +211.8%+5.9%129.0%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$107.79M +391.1%-58.2%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$60.96M -388.6%-1.9%18297.5%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$24.54M +1.8%-10.4%1070.2%
CUECue Biopharma, Inc.LTM Mar 2026$19.52M -51.9%-20.5%59.6%
EQEquillium, Inc.LTM Mar 2026$19.06M +36.2%-28.9%—
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$12.72M +12.6%-31.8%899.5%
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$9.22M -26.0%+130.2%—
Peer median (excluding COEP) $42.75M+19.0%-6.1%599.6%

Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.45M)(37.57M)(21.27M)(10.88M)(11.92M)
Depreciation & Amortization447.41K1M1.04M1.04M1.22M
Deferred Income Tax5.34M0000
Stock-Based Compensation1.9M0477.5K1.1M1.22M
Change in Working Capital(2.98M)(550.34K)1.73M(125.26K)(1.46M)
Accounts Receivables21.79K(8.08K)(30.9K)(234.74K)(7.35K)
Inventory(422.02K)0000
Accounts Payables(1.58M)(35.07K)1.32M(149.94K)(381.01K)
Other Working Capital(1M)(507.19K)437.31K259.42K(1.07M)
Other Non-Cash Items4.26M33.25M10.79M2.21M2.34M
Operating Cash Flow(4.49M)(3.88M)(7.24M)(6.65M)(8.6M)
Capital Expenditures(1.75M)0000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(1.75M)0000
Debt Repayment(1.62M)(2.42M)(575K)1.2M771.25K
Common Stock Issued10.14M3.27M5.29M100K12.97M
Common Stock Repurchased(247.17K)0000
Dividends Paid00000
Other Financing Activities(50.9K)4.63M200K500K0
Financing Cash Flow8.22M5.49M4.92M5.71M13.74M
Effect of Forex Changes00000
Net Change in Cash1.98M1.61M(2.32M)(936.25K)5.14M
Free Cash Flow(6.24M)(3.88M)(7.24M)(6.65M)(8.6M)

Coeptis Therapeutics, Inc.

NASDAQ:COEP

Intrinsic Alpha fair value

Locked

Current Price

$14.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.